S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.05%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
NASDAQ:GLSI

Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

$19.94
-0.06 (-0.30%)
(As of 04:00 PM ET)
Today's Range
$19.71
$20.55
50-Day Range
$8.31
$20.32
52-Week Range
$7.58
$21.44
Volume
27,726 shs
Average Volume
47,935 shs
Market Capitalization
$256.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

Greenwich LifeSciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
81.5% Upside
$36.00 Price Target
Short Interest
Healthy
2.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.22mentions of Greenwich LifeSciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$270,482 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.68) to ($0.76) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.06 out of 5 stars

Medical Sector

365th out of 938 stocks

Pharmaceutical Preparations Industry

166th out of 433 stocks

GLSI stock logo

About Greenwich LifeSciences Stock (NASDAQ:GLSI)

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

GLSI Stock Price History

GLSI Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
2 Rare Insider Buys in a Frothy Market
Greenwich: Closed pub reopens as community hub
See More Headlines
Receive GLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GLSI
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.00
High Stock Price Target
$36.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+81.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.03 per share

Miscellaneous

Free Float
6,057,000
Market Cap
$255.33 million
Optionable
Not Optionable
Beta
1.21
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

GLSI Stock Analysis - Frequently Asked Questions

Should I buy or sell Greenwich LifeSciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLSI shares.
View GLSI analyst ratings
or view top-rated stocks.

What is Greenwich LifeSciences' stock price target for 2024?

1 brokerages have issued 12 month price objectives for Greenwich LifeSciences' shares. Their GLSI share price targets range from $36.00 to $36.00. On average, they expect the company's stock price to reach $36.00 in the next twelve months. This suggests a possible upside of 81.5% from the stock's current price.
View analysts price targets for GLSI
or view top-rated stocks among Wall Street analysts.

How have GLSI shares performed in 2024?

Greenwich LifeSciences' stock was trading at $10.52 at the beginning of 2024. Since then, GLSI stock has increased by 88.5% and is now trading at $19.83.
View the best growth stocks for 2024 here
.

Are investors shorting Greenwich LifeSciences?

Greenwich LifeSciences saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 137,100 shares, an increase of 13.0% from the February 29th total of 121,300 shares. Based on an average daily volume of 45,400 shares, the days-to-cover ratio is currently 3.0 days. Approximately 2.4% of the shares of the company are sold short.
View Greenwich LifeSciences' Short Interest
.

When is Greenwich LifeSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our GLSI earnings forecast
.

When did Greenwich LifeSciences IPO?

Greenwich LifeSciences (GLSI) raised $7 million in an initial public offering on Friday, September 25th 2020. The company issued 1,300,000 shares at $5.75 per share. Aegis Capital served as the underwriter for the IPO.

Who are Greenwich LifeSciences' major shareholders?

Greenwich LifeSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.73%), Vanguard Group Inc. (1.73%) and Northern Trust Corp (0.16%). Insiders that own company stock include David Mcwilliams, Frank Joseph Daugherty, Jaye Thompson, Kenneth Hallock and Snehal Patel.
View institutional ownership trends
.

How do I buy shares of Greenwich LifeSciences?

Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLSI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners